CellSource Co (4880.T) Stock Price

CellSource Co Price

🇯🇵JPX·CLOSED
361.00JPY
Market closed
Today +/-
Today %

CellSource Co (4880.T) Stock | ISIN JP3423580004. The current CellSource Co stock price is 361 JPY (2026). Revenue is 3.49 B JPY. Net income is -122.17 M JPY. The P/E ratio is -58.55. Market capitalization is 7.16 B JPY. CellSource Co operates in the Health sector.

Over the last 8 years CellSource Co grew revenue by 27.9% annually, reaching 3.71 B JPY. Earnings per share have declined at 29.3% per year over the last 8 years. For CellSource Co, the net margin of 0.3% is down versus 22.3% a few years ago. At today's price the dividend yield works out to roughly 1.39%.

CellSource Co stock price

Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of CellSource Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how CellSource Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing CellSource Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

CellSource Co Stock Price History
DateCellSource Co Price
Access this data via the Eulerpool API

CellSource Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
519.06 M JPY
159.16 M JPY
111.4 M JPY
Jan 1, 2018
1.21 B JPY
295.09 M JPY
193.4 M JPY
Jan 1, 2019
1.61 B JPY
326.94 M JPY
199.61 M JPY
Jan 1, 2020
1.86 B JPY
415.55 M JPY
274.08 M JPY
Jan 1, 2021
2.92 B JPY
992.44 M JPY
651.4 M JPY
Jan 1, 2022
4.27 B JPY
1.57 B JPY
1.02 B JPY
Jan 1, 2023
4.51 B JPY
1.22 B JPY
923.14 M JPY
Jan 1, 2024
4.36 B JPY
129.16 M JPY
237.94 M JPY
Jan 1, 2025
3.71 B JPY
166.71 M JPY
10.66 M JPY
Invalid Date
3.49 B JPY
0 JPY
-122.17 M JPY
Invalid Date
3.74 B JPY
0 JPY
0 JPY
Invalid Date
4.14 B JPY
0 JPY
152.22 M JPY

CellSource Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 16, 2026, 6:15 AM
 
REVENUE (B JPY)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B JPY)
NET INCOME (B JPY)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
202120222023202420252026e2027e2028e
2.924.274.514.363.713.493.744.14
57.5246.245.55-3.44-14.79-6.097.2310.81
70.9871.7170.6255.556.2459.8955.8550.4
2.073.063.192.422.092.092.092.09
0.651.020.920.240.01-0.1200.15
137.5956.22-9.24-74.32-95.78-1,320
19.2119.2119.2619.8919.8119.8119.8119.81
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales CellSource Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue CellSource Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare CellSource Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares CellSource Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against CellSource Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

CellSource Co stock margins

The CellSource Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CellSource Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CellSource Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
57.78 %
30.66 %
21.46 %
Jan 1, 2018
72.23 %
24.33 %
15.95 %
Jan 1, 2019
71.58 %
20.29 %
12.39 %
Jan 1, 2020
67.85 %
22.4 %
14.77 %
Jan 1, 2021
70.97 %
33.96 %
22.29 %
Jan 1, 2022
71.7 %
36.76 %
23.82 %
Jan 1, 2023
70.61 %
27.08 %
20.47 %
Jan 1, 2024
55.51 %
2.97 %
5.46 %
Jan 1, 2025
56.24 %
4.49 %
0.29 %
Invalid Date
56.24 %
0 %
-3.51 %
Invalid Date
56.24 %
0 %
0 %
Invalid Date
56.24 %
0 %
3.68 %

CellSource Co Stock Revenue, EBIT, Earnings per Share

The CellSource Co earnings per share therefore indicates how much revenue CellSource Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
40.05 JPY
12.28 JPY
8.6 JPY
Jan 1, 2018
93.57 JPY
22.77 JPY
14.92 JPY
Jan 1, 2019
123.43 JPY
25.04 JPY
15.29 JPY
Jan 1, 2020
96.99 JPY
21.72 JPY
14.33 JPY
Jan 1, 2021
152.14 JPY
51.67 JPY
33.91 JPY
Jan 1, 2022
222.45 JPY
81.77 JPY
52.98 JPY
Jan 1, 2023
234.18 JPY
63.42 JPY
47.93 JPY
Jan 1, 2024
218.91 JPY
6.49 JPY
11.96 JPY
Jan 1, 2025
187.31 JPY
8.41 JPY
0.54 JPY
Invalid Date
175.74 JPY
0 JPY
-6.16 JPY
Invalid Date
188.45 JPY
0 JPY
0 JPY
Invalid Date
208.83 JPY
0 JPY
7.68 JPY

CellSource Co business model & stock analysis

CellSource Co., Ltd. engages in regenerative medicine related business. The company is headquartered in Shibuya-Ku, Tokyo-To and currently employs 109 full-time employees. The company went IPO on 2019-10-28. The firm operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.

CellSource Co Eulerpool Fair Value

CellSource Co historical P/E ratio, EBIT multiple, and P/S ratio

CellSource Co annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

CellSource Co shares outstanding

The number of shares was CellSource Co in 2025 — This indicates how many shares 19.814 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
12.96 M base_Shares
Jan 1, 2018
12.96 M base_Shares
Jan 1, 2019
13.06 M base_Shares
Jan 1, 2020
19.13 M base_Shares
Jan 1, 2021
19.21 M base_Shares
Jan 1, 2022
19.21 M base_Shares
Jan 1, 2023
19.26 M base_Shares
Jan 1, 2024
19.89 M base_Shares
Jan 1, 2025
19.81 M base_Shares
Invalid Date
19.81 M base_Shares
Invalid Date
19.81 M base_Shares
Invalid Date
19.81 M base_Shares

CellSource Co Dividend History

3 years of dividend payments

YearAnnual DividendYoY ChangePayments
20255JPY 0.0%
Oct 30, 20255JPY 0.0%1/1
20245JPY 0.0%
20235JPY

CellSource Co dividend history and estimates

In 2025, CellSource Co paid a dividend amounting to 5 JPY. Dividend means that CellSource Co distributes a portion of its profits to its owners.
  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Invalid Date
0 JPY
5 JPY
Invalid Date
5 JPY
5 JPY
Jan 1, 2025
5 JPY
0 JPY
Price targets and forecasts for CellSource Co are not yet available.

CellSource Co shareholder structure

% Name
36.177%
Yamakawa (Masayuki)
Yamakawa (Masayuki)
9.58548%
Serial Incubate KK
Serial Incubate KK
6.83812%
Tsumamoto (Masato)
Tsumamoto (Masato)
1.82703%
Baillie Gifford & Co.
Baillie Gifford & Co.
1.76251%
Nomura Asset Management Co., Ltd.
Nomura Asset Management Co., Ltd.
1.65816%
SBI Securities Co., Ltd.
SBI Securities Co., Ltd.
1.04874%
Nikko Asset Management Co., Ltd.
Nikko Asset Management Co., Ltd.
0.80971%
Daiwa Asset Management Co., Ltd.
Daiwa Asset Management Co., Ltd.
0.60161%
Kida (Junichi)
Kida (Junichi)
0.44276%
BNP Paribas Arbitrage SA
BNP Paribas Arbitrage SA

CellSource Co Executives and Management Board

MY

Dr. Masayuki Yamakawa

(61)

Chairman of the Board, Representative Director · since 2015

TS

Mr. Takashi Sawada

(68)

President, Chief Executive Officer, Representative Director · since 2022

KH

Ms. Kaoru Hosoda

Executive Officer, Chief Operating Officer, Chief Director of Contract Processing Business

TI

Mr. Tomohiro Iga

Executive Officer

YH

Mr. Yuta Hayashi

Executive Officer, Chief Strategy Officer, Chief Director of Business Strategy

CellSource Co Supply Chain

Frequently asked questions about CellSource Co

All fundamentals and in-depth analysis of CellSource Co

Our stock analysis for CellSource Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CellSource Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.